leadf
logo-loader
viewImmunoPrecise Antibodies Ltd

Immunoprecise Antibodies surges after opening new B-cell facility

The new facility's technology greatly increases the speed of antibody discovery platforms and maintains native antibody pairing

Blood cells
With the launch of its new facility, the company is able "to guarantee the outcomes of producing target specific antibodies for each campaign"

Shares in Immunoprecise Antibodies Ltd (CVE:IPA) shot up after it said its new facility for sorting B-cells is now open.

Immunoprecise's full-service facility offers B-cell screening, sorting and sequencing on a broad range of therapeutically-relevant protein families including G protein coupled receptors (GPCRs) and other multi-membrane spanning proteins.

READ: Immunoprecise Antibodies shares surge as it posts record revenue in third quarter​

The new facility means Immunoprecise can now do B-cell services in-house, which will greatly increases the profit margin of the services it offers.

The addition of the B-cell sorting facility completes the company's full service platform for the antibody discovery process of antibodies and is expected to be followed by the opening of a similar facility in Europe in the second half of 2018.

A B-cell is a type of white blood cell that is vital to the body's immune system.

"B-cell screening, sorting and sequencing capability provides enhanced technological capacity that substantially increases throughput and identification [of] therapeutically relevant antibodies," said Jennifer Bath, the president and chief executive officer of Immunoprecise (IPA).

"The industry has increasingly identified its needs to out-source its antibody discovery process to a single source provider who has the technical and technological capability for high throughput and higher probability of identifying therapeutically relevant antibodies," she added.

"We anticipate IPA's global footprint and antibody discovery industry leadership will enable the further growth and expansion of our platform," she declared.

Shares in Immunoprecise were up by a fifth at C$0.90.

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 2.02 CAD

TSX-V:IPA
Market: TSX-V
Market Cap: $161.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmunoPrecise Antibodies reveals 39% growth in 1Q revenue, initiates...

ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study. Bath says new...

3 weeks, 6 days ago

2 min read